We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

24 hedge funds and large institutions have $3.22M invested in Cellectar Biosciences in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

50% more capital invested

Capital invested by funds: $2.14M → $3.22M (+$1.08M)

20% more funds holding

Funds holding: 20 → 24 (+4)

0.33% more ownership

Funds ownership: 0.35% → 0.67% (+0.33%)

Holders
24
Holders Change
+4
Holders Change %
+20%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
+$1.51M
2
WVP
Worth Venture Partners
New Jersey
+$589K
3
CH
CVI Holdings
Delaware
+$332K
4
Renaissance Technologies
Renaissance Technologies
New York
+$58K
5
AS
Altshuler Shaham
Israel
+$40K

Top Sellers

Rank Fund Capital Flow
1
DCM
Difesa Capital Management
New York
-$34K
2
IA
IFP Advisors
Florida
-$1K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$180
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$1.59M +$1.51M +25,249 +434%
WVP
2
Worth Venture Partners
New Jersey
$576K +$589K +9,832 +708%
Vanguard Group
3
Vanguard Group
Pennsylvania
$300K +$180 +3 +0.1%
CH
4
CVI Holdings
Delaware
$284K +$332K +5,535 New
BlackRock
5
BlackRock
New York
$97.5K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$82K +$7.19K +120 +8%
Renaissance Technologies
7
Renaissance Technologies
New York
$80K +$58K +968 +164%
MS
8
Maven Securities
Jersey
$42.8K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$31.9K +$37.3K +622 New
State Street
10
State Street
Massachusetts
$26.9K – – –
Morgan Stanley
11
Morgan Stanley
New York
$25.6K – – –
Bank of New York Mellon
12
Bank of New York Mellon
New York
$20.6K -$180 -3 -0.7%
1WM
13
1900 Wealth Management
Texas
$20.5K – – –
Franklin Resources
14
Franklin Resources
California
$17.7K – – –
TRCT
15
Tower Research Capital (TRC)
New York
$13K +$12.6K +210 +420%
UBS Group
16
UBS Group
Switzerland
$2.82K – – –
Osaic Holdings
17
Osaic Holdings
Arizona
$1K – – –
TFA
18
Transamerica Financial Advisors
Florida
$1K – – –
US Bancorp
19
US Bancorp
Minnesota
$487 – – –
MWM
20
MinichMacGregor Wealth Management
New York
$239 +$300 +5 New
Wells Fargo
21
Wells Fargo
California
$94 +$60 +1 +100%
HI
22
Harbour Investments
Wisconsin
$68 +$60 +1 New
Bank of America
23
Bank of America
North Carolina
$34 +$60 +1 New
AWM
24
AllSquare Wealth Management
New York
$31 – – –
DCM
25
Difesa Capital Management
New York
– -$34K -333 Closed
1
2

CLRB Hedge Fund Activity: Q4 2022 in Review

24 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2022, worth a combined $3.22M — up 50% from $2.14M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CLRB positions and 1 closed out — a net gain of 5 holders — while 7 added to existing stakes and 1 trimmed.

The largest buyer was AIGH Capital Management, adding an estimated $1.51M. The largest seller was Difesa Capital Management, exiting entirely with an estimated $34K sold.

  • 24 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2022, up from 20 in Q3 2022.
  • Funds reported $3.22M of Cellectar Biosciences stock for Q4 2022, up 50% quarter-over-quarter.
  • 6 funds opened new Cellectar Biosciences positions in Q4 2022 and 1 closed out, a net change of +5 holders.
  • The largest Cellectar Biosciences buyer in Q4 2022 was AIGH Capital Management, an estimated $1.51M added.
  • The largest Cellectar Biosciences seller in Q4 2022 was Difesa Capital Management, an estimated $34K sold.

Based on aggregated 13F filings for Q4 2022.